Steven Hoerter was named President and Chief Executive Officer of MBX Biosciences, Inc., effective July 13, 2026. As of November 6, 2026, MBX Biosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 13, 2026 to October 22, 2026, naming 2 appointments (Form 8-K, July 13, 2026).
Who owns MBX Biosciences, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like MBX Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
MBX Biosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-13 to 2026-10-22. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as MBX Biosciences, Inc. files it.
Also on the record for MBX Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 15% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 3.64% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13D/A, by Frazier Life Sciences Public Fund, L.P. | 11.7% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 6.4% of the class | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.5% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.2% of the class | 5%+ stakes | Source |
| July 8, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 10.5% of the class | 5%+ stakes | Source |
| June 24, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 5.2% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 6.2% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.8% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13D/A, by ORBIMED ADVISORS LLC | 7.7% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 7.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs MBX Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on MBX Biosciences, Inc. and the records around it.
MBX Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- IPO filing Sep 2025
- Who owns it
Companies that share a holder
- Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. also filed stake reports on 2 other companies: Korsana Biosciences, Inc. (Sep 2026), ProMIS Neurosciences, Inc. (Aug 2026)
- New Enterprise Associates 17, L.P. also filed stake reports on 4 other companies: Monte Rosa Therapeutics, Inc. (Jul 2026), Inventiva S.A. (Apr 2026), Korro Bio, Inc. (Mar 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
Watch MBX Biosciences, Inc.
Get an email when MBX Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on MBX Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on MBX Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on MBX Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 28 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-22 | In | Director | 2026-10-20 | 8-K, 2026-10-22 | |
| 2026-07-13 | In | President and Chief Executive Officer | 2026-07-13 | 8-K, 2026-07-13 |
Who leads MBX Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Peter Radovich, appointed, effective 2026-10-20 (filed 2026-10-22).
- President and Chief Executive Officer: Steven Hoerter, appointed, effective 2026-07-13 (filed 2026-07-13).
New leaders reset buying decisions — get the Full Report on MBX Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at MBX Biosciences, Inc., with the record behind each one.
Find candidates like Director at MBX Biosciences, Inc.Every change, in the filing's words
Appointed: Peter Radovich, Director, effective 2026-10-20
Effective as of October 20, 2026, the board of directors (the "Board") of MBX Biosciences, Inc. (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the "NCG Committee"), appointed Peter Radovich as a director of the Company.
- The Board determined that Mr. Radovich is independent under the applicable listing standards of The Nasdaq Stock Market ("Nasdaq").
- Mr. Radovich has been designated as a Class I director to serve until the Company's 2028 Annual Meeting of Stockholders, in accordance with the Company's amended and restated by-laws and to serve thereafter until his successor has been duly elected and qualified or until his earlier death, removal or resignation.
- In connection with the appointment, the Board set the size of the Board at eight directors.
- In connection with his appointment as a non-employee director, Mr. Radovich will receive compensation, including an initial award of a non-qualified stock option to purchase 18,200 shares of the Company's common stock, to be granted on the appointment date of October 20, 2026.
- In addition, Mr. Radovich will receive cash compensation for his Board service, in accordance with the Company's Non-Employee Director Compensation Policy (as amended March 2026), which was previously described in the Company's Annual Proxy Statement for the period ending December 31, 2025, filed with the Securities and Exchange Commission on April 22, 2026.
- In addition, in connection with his election, the Company is entering into an indemnification agreement with Mr. Radovich in the same form as used with the Company's other directors.
Appointed: Steven Hoerter, President and Chief Executive Officer, effective 2026-07-13
On July 9, 2026, the Board appointed Steven Hoerter, the Company's current executive Chairman of the Board, as President and Chief Executive Officer and principal executive officer of the Company, effective as of July 13, 2026 (the " Effective Date ").
- Departure of Chief Executive Officer Kent P. Hawryluk will be stepping away from his role as the Company's Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026.
- Following his last date of employment, Dr. Hawryluk will assist the Board and the Company's new Chief Executive Officer with the transition and will provide strategic advisory services through August 16, 2026 under the terms of a consulting agreement entered into with the Company that will become effective upon Dr. Hawryluk's separation from the Company.
- Dr. Hawryluk's departure is not due to a dispute or disagreement with the Company or the Company's auditors.
- In connection with Dr. Hawryluk's separation from the Company, on July 13, 2026, the Company and Dr. Hawryluk entered into a separation agreement (the "Separation Agreement").
- In addition, subject to compliance with applicable law and the terms of the applicable equity award agreements and equity incentive plan, the Company will extend the post-termination exercise period for Dr. Hawryluk's outstanding vested stock options from the standard 90-day period until July 13, 2027.
Tools for this story
Each opens in a new tab, filled in for MBX Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.